Jump to a section
- Research scope and peptide identity
- Mechanisms discussed in cited studies
- Study models and experimental designs
- Outcomes measured in the reviewed sources
- Reported study-design and protocol details
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Tesamorelin research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
This overview summarizes reported mechanisms and study designs for tesamorelin as described in the provided regulatory documents, clinical trials, and reviews.
Research scope and peptide identity
Tesamorelin is described in regulatory and review sources as a growth hormone–releasing factor (GHRF) analogue used to reduce excess abdominal visceral adipose tissue (VAT) in people with HIV and lipodystrophy; FDA labeling and contemporary summaries identify it as the marketed product Egrifta and document its approved indication for HIV‑associated abdominal fat accumulation. [S3] [S7] [S9]
Clinical pharmacology review material characterizes tesamorelin chemically as a stabilized 44‑amino‑acid human GHRH analogue with an N‑terminal hexenoyl modification intended to improve stability. [S8]
Mechanisms discussed in cited studies
Reviewed sources describe tesamorelin’s primary mechanism as activation of pituitary GHRH receptors, producing increases in growth hormone (GH) and consequent rises in circulating IGF‑1 (hepatic IGF‑1), which are linked in trial reports and labeling to downstream effects on body composition including reductions in VAT. [S7] [S9] [S1]
Study models and experimental designs
Pivotal development and registration trials are summarized in FDA labeling as randomized, double‑blind, placebo‑controlled trials using a 26‑week (approximately 6‑month) primary endpoint measuring percent change in CT‑measured VAT at the L4–L5 vertebral level. [S7]
Primary literature reports a Phase 3 randomized, double‑blind trial in HIV‑infected patients with central adiposity that used CT‑measured VAT as the primary endpoint over a 6‑month treatment period. [S10]
A more recent randomized, double‑blind analysis of tesamorelin in people with HIV (PWH) on integrase inhibitor (INSTI) regimens evaluated tesamorelin versus placebo within a parent trial of metabolic dysfunction‑associated steatotic liver disease, incorporating imaging modalities including MRI, proton magnetic resonance spectroscopy (MRS), and dual‑energy x‑ray absorptiometry (DXA). [S5]
Regulatory clinical pharmacology review documents summarize early phase pharmacokinetic/pharmacodynamic (PK/PD) assay development and structural stabilization strategies for the peptide. [S8]
Outcomes measured in the reviewed sources
Primary and secondary outcomes reported across the reviewed trials include percent change in CT‑measured visceral adipose tissue (VAT), CT or cross‑sectional visceral fat area, hepatic fat fraction measured by proton MRS, trunk‑to‑appendicular fat ratio assessed by DXA, and anthropometric trunk/waist measures. [S7] [S10] [S5]
Biomarker and safety outcomes explicitly reported include increases in circulating IGF‑1 and assessments of glycemic control and adverse events, with one trial reporting no exacerbation of glycemic control and similar adverse event frequency between tesamorelin and placebo arms. [S10] [S5] [S7]
Some trial reports note that VAT‑reducing effects diminished after treatment discontinuation. [S10]
Reported study-design and protocol details
A randomized, double‑blind comparison within a parent trial examined tesamorelin 2 mg once daily versus identical placebo among people with HIV on INSTI‑based antiretroviral regimens, with baseline and 12‑month imaging (MRI, proton MRS, DXA) and comparisons of visceral fat area, hepatic fat fraction, and trunk‑to‑appendicular fat ratio between arms. [S5]
Phase 3 randomized, double‑blind, placebo‑controlled trials used a 6‑month (26‑week) primary endpoint of percent change in CT‑measured VAT (L4–L5) as reported in pivotal trial summaries and regulatory labeling; these trials reported significant VAT reduction versus placebo and increases in IGF‑1, with observed waning of effect after discontinuation. [S7] [S10]
Regulatory clinical pharmacology materials describe tesamorelin’s peptide stabilization strategy and early PK/PD assay development but do not provide a detailed dosing schedule within the reviewed excerpt. [S8]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S5] | Randomized, double-blind, placebo-controlled trial (analysis nested in parent RCT) | People with HIV on integrase inhibitor (INSTI)-based regimens with metabolic dysfunction-associated steatotic liver disease | 2 mg | not reported in the reviewed source | once daily | 12 months | Primary imaging and body composition endpoints included visceral fat cross-sectional area (MRI), hepatic fat fraction (proton MRS), and trunk-to-appendicular fat ratio (DXA); tesamorelin arm showed significant declines in VAT, hepatic fat, and trunk-to-appendicular ratio vs placebo. |
| [S10] | Phase 3 randomized, double-blind, placebo-controlled trial | HIV-infected patients with abdominal fat accumulation | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | 6 months | Primary endpoint was percent change in CT-measured visceral adipose tissue (VAT); reported outcomes included significant VAT reduction versus placebo, rises in IGF-1, improved waist/trunk measures, and waning of effect after discontinuation. |
| [S7] | Pivotal randomized, double-blind, placebo-controlled trials (FDA labeling summary) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | 26 weeks (primary endpoint reported) | FDA labeling summarizes primary endpoint as percent change in CT‑measured VAT at L4–L5 over the 26‑week period. |
| [S8] | Regulatory clinical pharmacology review | not applicable | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Describes tesamorelin as a stabilized 44‑amino‑acid human GHRH analog with an N‑terminal hexenoyl modification and summarizes early phase PK/PD assay development. |
Limitations and research gaps
- Most reviewed clinical data and regulatory summaries pertain to HIV‑associated abdominal fat accumulation; reviewed sources do not provide evidence for use in orthopaedic indications.
- Several excerpts summarize trial endpoints and outcomes but omit explicit procedural details in the reviewed excerpts (for example, route of administration is not stated in the provided excerpts).
- Longer‑term outcomes beyond trial durations and broader safety datasets outside the reported HIV populations are not available in the provided excerpts.
- Some review articles note a lack of clinical trials for peptide applications outside their approved indications.
Documentation checklist
- Confirm indication and pivotal trial details by consulting the full FDA prescribing information.
- Cross-reference primary trial publications for complete protocol and safety tables when extracting dosing and administration details.
- Verify imaging and endpoint methodologies (CT slice level, MRI/MRS protocols, DXA analysis) in source trial methods before secondary analysis.
- Note whether trial populations match the population of interest (e.g., antiretroviral regimen, comorbid liver disease) when interpreting results.
Related research supplies
- FDA prescribing information PDF (regulatory labeling document)
- Clinical trial imaging protocol templates (CT, MRI/MRS, DXA) for data documentation
- Regulatory and clinical pharmacology review documents for archival reference and study metadata
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S3] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin.. Nature reviews. Drug discovery. 2011. PMID: 21283099. DOI: 10.1038/nrd3362
- [S4] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S5] Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.. AIDS (London, England). 2024. PMID: 38905488. DOI: 10.1097/QAD.0000000000003965
- [S6] O'Neal R. Tesamorelin update.. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 2010. PMID: 21591600
- [S7] EGRIFTA WR (tesamorelin) Highlights of Prescribing Information. official. PMID:
- [S8] CENTER FOR DRUG EVALUATION AND RESEARCH: Clinical Pharmacology and Biopharmaceutics Review (NDA 22‑505). official. PMID:
- [S9] Tesamorelin – LiverTox – NCBI Bookshelf. official. PMID:
- [S10] Effects of tesamorelin, a growth hormone–releasing factor, in HIV‑infected patients with abdominal fat accumulation: a randomized placebo‑controlled trial with a safety extension. primary literature. PMID:
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.